Susan Hogan to Antibodies, Antineutrophil Cytoplasmic
This is a "connection" page, showing publications Susan Hogan has written about Antibodies, Antineutrophil Cytoplasmic.
Connection Strength
3.130
-
Hogan SL, Cooper GS, Savitz DA, Nylander-French LA, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette JC, Falk RJ. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol. 2007 Mar; 2(2):290-9.
Score: 0.264
-
Hogan SL, Falk RJ, Nachman PH, Jennette JC. Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2006 Mar 07; 144(5):377-8; author reply 378-9.
Score: 0.248
-
Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005 Nov 01; 143(9):621-31.
Score: 0.242
-
Chen DP, Aiello CP, McCoy D, Stamey T, Yang J, Hogan SL, Hu Y, Derebail VK, Wu EY, Jennette JC, Falk RJ, Ciavatta DJ. PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease. JCI Insight. 2023 02 22; 8(4).
Score: 0.201
-
Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol. 2001 Jan; 12(1):134-142.
Score: 0.173
-
Jones BE, Herrera CA, Agosto-Burgos C, Starmer J, Bass WA, Poulton CJ, Blazek L, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, Wu EY, Chen DP, Jennette JC, Free ME, Falk RJ, Ciavatta DJ. ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation. Kidney Int. 2020 09; 98(3):744-757.
Score: 0.166
-
Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, Poulton CJ, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, Nachman PH, Jennette JC, Falk RJ, Bunch DO. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019 11; 71(11):1894-1903.
Score: 0.159
-
Free ME, Stember KG, Hess JJ, McInnis EA, Lardinois O, Hogan SL, Hu Y, Mendoza C, Le AK, Guseman AJ, Pilkinton MA, Bortone DS, Cowens K, Sidney J, Karosiene E, Peters B, James E, Kwok WW, Vincent BG, Mallal SA, Jennette JC, Ciavatta DJ, Falk RJ. Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. J Autoimmun. 2020 01; 106:102306.
Score: 0.157
-
Weiner M, Bj?rneklett R, Hru?kov? Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasar?d K, Segelmark M. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2019 02 01; 34(2):301-308.
Score: 0.152
-
McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i171-81.
Score: 0.116
-
Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012 Oct; 64(10):3452-62.
Score: 0.098
-
Cao Y, Yang J, Colby K, Hogan SL, Hu Y, Jennette CE, Berg EA, Zhang Y, Jennette JC, Falk RJ, Preston GA. High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLoS One. 2012; 7(8):e42783.
Score: 0.097
-
Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung Hc, Bunch DO, McGregor JG, Hogan SL, Hu Y, Yang JJ, Berg EA, Niles J, Jennette JC, Preston GA, Falk RJ. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol. 2012 Mar; 23(3):545-55.
Score: 0.092
-
Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
Score: 0.083
-
Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009 Sep; 76(6):644-51.
Score: 0.078
-
Carpenter DM, Thorpe CT, Lewis M, Devellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum. 2009 Feb 15; 61(2):259-65.
Score: 0.076
-
Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, Hogan SL, Chin H, Moll S, Jennette JC, Falk RJ. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008 Dec; 19(12):2421-9.
Score: 0.073
-
Yang J, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, Schmitz JL, Pressler BM, Jennette JC, Falk RJ, Preston GA. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int. 2008 Nov; 74(9):1159-69.
Score: 0.073
-
Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant. 2007 Dec; 22(12):3508-15.
Score: 0.068
-
Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005 Dec; 20(12):2725-32.
Score: 0.060
-
Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol. 2004 Aug; 15(8):2103-14.
Score: 0.056
-
Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003 Dec; 42(6):1149-53.
Score: 0.053
-
Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol. 2003 Sep; 10(5):769-74.
Score: 0.052
-
Cao B, Hogan SL, Derebail VK, Ehlert A, Thorpe CT. Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis. J Manag Care Spec Pharm. 2023 Jul; 29(7):770-781.
Score: 0.051
-
Yang JJ, Preston GA, Alcorta DA, Waga I, Munger WE, Hogan SL, Sekura SB, Phillips BD, Thomas RP, Jennette JC, Falk RJ. Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). Kidney Int. 2002 Nov; 62(5):1638-49.
Score: 0.049
-
Huang SP, Li X, Cao B, Nguyen JT, Robinson JE, Derebail VK, Hogan SL, Thorpe CT. Health care costs and utilization prior to diagnosis of antineutrophil cytoplasmic antibody vasculitis in Medicare beneficiaries. J Manag Care Spec Pharm. 2022 Nov; 28(11):1292-1303.
Score: 0.049
-
Chen DP, McInnis EA, Wu EY, Stember KG, Hogan SL, Hu Y, Henderson CD, Blazek LN, Mallal S, Karosiene E, Peters B, Sidney J, James EA, Kwok WW, Jennette JC, Ciavatta DJ, Falk RJ, Free ME. Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity. J Am Soc Nephrol. 2022 08; 33(8):1517-1527.
Score: 0.048
-
McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i123-31.
Score: 0.029
-
Cao Y, Liu K, Tian Z, Hogan SL, Yang J, Poulton CJ, Falk RJ, Li W. PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis. J Rheumatol. 2015 Feb; 42(2):292-9.
Score: 0.028
-
Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother. 2009 Jun; 43(6):1020-7.
Score: 0.019
-
Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC. Vasculitis and anti-thyroid medication. Nephrol Dial Transplant. 2008 May; 23(5):1766-8; author reply 1768.
Score: 0.018